Larimar Therapeutics Has Priced The Public Offering Of 17.16M Shares At $8.74/Share For Gross Proceeds Of Approximately $150M
Portfolio Pulse from Benzinga Newsdesk
Larimar Therapeutics has announced the pricing of its public offering of 17.16 million shares at $8.74 per share, aiming to raise approximately $150 million in gross proceeds.
February 14, 2024 | 11:18 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Larimar Therapeutics is raising approximately $150 million through a public offering of 17.16 million shares priced at $8.74 each.
The announcement of a public offering can have mixed impacts on a company's stock price. On one hand, it can dilute existing shareholders, potentially leading to a short-term decrease in stock price. On the other hand, the influx of capital can be viewed positively if investors believe it will be used for growth-enhancing projects. Given the size of the offering and the specific price point, the short-term impact is assessed as neutral until the market's reception of this offering becomes clear.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100